Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Centronuclear Myopathy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...

DelveInsight’s, “Obesity - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug ...

CARLSBAD, Calif. and STRASBOURG, France, Nov. 9, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5 Rx (Dyn101), a ...

Data Bridge Market Research Added new upcoming report title “Centronuclear Myopathies Drug Market Study 2026: Poised For A Strong Growth By Eminent Players – Audentes Therapeutics, Ionis ...

Myopathy is a general medical term used to describe a group of disorders that affect skeletal muscle fibers, leading to muscle weakness. Centronuclear myopathies (CNM) are a group of rare and ...

(Stuttgart/Braunschweig): ZNM - Zusammen Stark! e. V. an association dedicated to supporting patients with rare muscle conditions known as centronuclear myopathies (CNM), is proud to announce the ...

Researchers from the University of Minnesota have identified the importance of a gene critical to normal muscle function, resulting in a new mouse model for a poorly understood muscle disease in ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 40 (October 4, 2022), pp. 1-10 (10 pages) X-linked centronuclear myopathy (XLCNM) is a severe human ...

Researchers from the University of Minnesota have identified the importance of a gene critical to normal muscle function, resulting in a new mouse model for a poorly understood muscle disease in ...

A French drugmaker that has licensed a treatment for rare genetic muscular disorders from a US firm plans to use money raised in a Series A funding round to conduct a clinical trial starting next year ...